NCT03358979 Three-dimensional Analysis of EMMPRIN on Conjunctival Epithelial Cells Surface in Severe Dry Eye Syndrome (ALTESSE)
| NCT ID | NCT03358979 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondation Ophtalmologique Adolphe de Rothschild |
| Condition | Conjunctival Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2017-12-14 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2017-12-14 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Modifications of cell surface markers (including EMMPRIN) were observed in conjunctival epithelial cells during dry eye syndrome ; this study aims to describe the modifications of the repartition of these cell surface markers before and after initiation of a treatment.
Eligibility Criteria
Patients: Inclusion criteria * 18 years and over * Severe eye dryness (grade 3 or 4) as defined by the International Dry Eye Work Shop (2007): Frequent symptoms, Impregnation of fluorescein at the conjunctival level, marked fluorescein staining at the corneal level, Tear Break Up Time ≤ 5 seconds (fluorescein test) Schirmer's test score without anesthesia ≤ 5mm at 5 minutes * Patients without eye treatment or patients undergoing long-term stable eye treatment for whom a new treatment is being introduced Exclusion criteria - Known pregnancy or breastfeeding Control subjects: Inclusion criteria \- 18 years and over Exclusion criteria * Wearer of contact lenses * Topical ocular treatment * Known pregnancy or breastfeeding
Contact & Investigator
Eric GABISON
PRINCIPAL INVESTIGATOR
Fondation Ophtalmologique A. de Rothschild
Frequently Asked Questions
Who can join the NCT03358979 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Conjunctival Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03358979 currently recruiting?
Yes, NCT03358979 is actively recruiting participants. Contact the research team at ayavchitz@for.paris for enrollment information.
Where is the NCT03358979 trial being conducted?
This trial is being conducted at Paris, France.
Who is sponsoring the NCT03358979 clinical trial?
NCT03358979 is sponsored by Fondation Ophtalmologique Adolphe de Rothschild. The principal investigator is Eric GABISON at Fondation Ophtalmologique A. de Rothschild. The trial plans to enroll 100 participants.